Back grey_arrow_rt.gif
 
Archived NATAP Articles from September 2003
 
null.gif
 
 
  1. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C - (9/30/03)
     
  2. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone - (9/30/03)
     
  3. Nadir Cd4 Count May Predict Immunity: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection - (9/30/03)
     
  4. HAART Interruption & Acute HIV Syndrome: Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions - (9/30/03)
     
  5. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women - (9/30/03)
     
  6. HAART Interruption & Drug Resistance: Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients - (9/30/03)
     
  7. ART & Hepatotoxicity: Alanine aminotransferase (ALT) decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy - (9/30/03)
     
  8. Hyperlactatemia in HIV: Frequency, risk factors and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy - (9/30/03)
     
  9. Progenics Awarded $28.6 Million NIH Contract to Develop Novel HIV/AIDS Vaccine; Progenics HIV Attachment Inhibitor - (9/30/03)
     
  10. NIH HIV Vaccine Program: NIAID AWARDS $81 MILLION FOR HIV VACCINE DEVELOPMENT - (9/30/03)
     
  11. Evaluation of Computed Tomography and Ultrasonography for Assessment of Facial Fat in HIV-Infected Patients - (9/29/03)
     
  12. Transmission of Hepatitis B and C Viruses in Outpatient Settings --- New York, Oklahoma, and Nebraska, 2000-2002 - (9/29/03)
     
  13. Trizivir Utility & Controversy - (9/26/03)
     
  14. Diabetes in HIV & HCV/HIV; prevalence, immunology - Written by Judith Aberg, MD, Washington University, St Louis, Missouri and ACTG - (9/25/03)
     
  15. IAS - 96 week results of Trizivir vs Combivir/Nelfinavir vs d4T/3TC/Nelfinavir: Trizivir story is not over yet - Written by Judith Aberg, MD, Washington University, St. Louis, Missouri and the ACTG - (9/25/03)
     
  16. ICAAC - ICAAC Summary Report - Written by David Margolis, MD, University of Texas, Southwestern Medical Center and Dallas VA Medical Center - (9/25/03)
     
  17. Schering-Plough to Initiate First Head-to-Head Study Of Leading Hepatitis C Therapies - (9/24/03)
     
  18. ICAAC - Two Year Analysis of Stavudine Extended-Release/Prolonged Release Capsules (XR/PRC) as Compared to Stavudine Immediate-Release (IR): Efficacy and Safety - Written by Judith Aberg, MD, Washington University, St. Louis, Missouri - (9/24/03)
     
  19. ICAAC - Saquinavir/Ritonavir (Sqv/R) Pharmacokinetics (Pks) In HIV+ Subjects: 1000/100 Mg Bid VS 1600/100 and 2000/100 Mg Once Daily (OD) - (9/23/03)
     
  20. ICAAC - Genetics and Virologic, Biochemical & Histologic Response to Pegylated Interferon and Ribavirin in HIV/HCV Co-infected Individuals - (9/22/03)
     
  21. Merck's Investigational HIV Vaccine Candidate to be Studied In Collaborative Clinical Trial to Begin in 18 Cities Around the World - (9/22/03)
     
  22. MaxCmin1 Study: SQV/rtv 1000/100 mg twice daily vs IDV/rtv - (9/22/03)
     
  23. ICAAC - D4T Once Daily 2-Year Follow-up: lipoatrophy and peripheral neuropathy, and antiviral activity - (9/22/03)
     
  24. ICAAC - PK Drug Interaction and Safety of Tenofovir and Kaletra - (9/22/03)
     
  25. ICAAC - Kaletra (Lopinavir/ritonavir) in Antiretroviral-Naive HIV-Infected Patients: 5-Year Follow-Up - (9/22/03)
     
  26. ICAAC - Dyslipidemia Improvement in Patients Switching from D4T to Tenofovir - Written by Judith Aberg, MD, Washington University, St louis, Missouri and the ACTG - (9/22/03)
     
  27. ICAAC - PK of Once daily Reyataz, DDI-EC, Tenofovir - (9/22/03)
     
  28. ICAAC - Switch from PI to Nevirapine: 3 yr follow-up, lipids, viral load - (9/19/03)
     
  29. Need for liver transplant in HIV-positive patients: first results of a specific survey in Italy, Project HOST - (9/19/03)
     
  30. ICAAC - Tenofovir and Norgestimate/Ethinyl Estradiol: lack of a pharmacokinetic drug interaction - (9/19/03)
     
  31. ICAAC - PK Drug Interaction and Safety of Tenofovir and Kaletra - (9/19/03)
     
  32. ICAAC - Similar 96-wk Renal Safety Profile of Tenofovir vs d4T: used in combination with 3TC/efavirenz in treatment-naïve patients - (9/19/03)
     
  33. ICAAC - Kaletra - Fosamprenavir Interaction Study - (9/18/03)
     
  34. ICAAC - Effects of High-Dose Vitamin C on the Steady State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers - (9/18/03)

    35.  
  35. ICAAC - Viral Failure to Tenofovir/Abacavir/3TC - (9/18/03)

    36.  
  36. ICAAC - Dyslipidemia Improvement After Switch From d4T to Tenofovir - (9/18/03)

    37.  
  37. ICAAC - Pilot Study of the Safety and Efficacy of Kaletra as Single Drug HAART in HIV+ ART Naïve Patients: interim analysis of subjects completing at least 24 weeks of a 48 week study - (9/17/03)

    38.  
  38. The Efficacy of Lopinavir in Individuals Experiencing Protease Inhibitor Failure - (9/17/03)

    39.  
  39. ICAAC - Abacavir Once Daily Study - (9/17/03)

    40.  
  40. Persistent immune activation in HIV-1 infection is associated with progression to AIDS - (9/15/03)

    41.  
  41. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration - (9/15/03)

    42.  
  42. DDI in Treatment Experienced HIV-infected Patients - (9/15/03)

    43.  
  43. ICAAC - UK-427,857 (HIV attachment inhibitor) - Day 1 at ICAAC, Chicago, Sept 13-17, 2003, Reported by Jules Levin - (9/15/03)

    44.  
  44. Pioglitazone in Lipodystrophy - (9/10/03)

    45.  
  45. Outcome and Management of Hepatitis C in Liver Transplant Recipients - (9/10/03)

    46.  
  46. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B - (9/10/03)

    47.  
  47. FDA Approves Valtrex for Reducing Risk For Sexual Transmission With Suppressive Therapy" FDA Updates Labeling of Valtrex source: Aug 29, 2003 FDA Talk Paper - (9/10/03)

    48.  
  48. AIDS ADVOCATES FEAR ADAP WAITING LISTS TO BECOME DEATH SENTENCE - (9/5/03)

    49.  
  49. Georgia State Budget Cuts Include HIV Program - (9/4/03)

    50.  
  50. ADAP Continues To Be In Crisis - (9/4/03)

    51.  
  51. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group (PDF) - (9/2/03)

    52.  
  52. How Does Expert Advice Impact Genotypic Resistance Testing in Clinical Practice? - (9/2/03)

    53.  
  53. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C - (9/2/03)

    54.  
  54. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in monoinfected patients with chronic hepatitis C - (9/2/03)

    55.  
  55. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies - (9/2/03)

    56.  
  56. Prisons plagued with Hepatitis C in Massachusetts - (9/2/03)

    57.